Effect of intracoronary Adenosine infusion during primary percutaneous coronary intervention in Acute Myocardial infarction

Effect of prophylactic intracoronary Adenosine infusion during primary percutaneous coronary intervention in Acute ST Elevation Myocardial infarction

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017062434621N1

Enrollment

104

Registered

2017-08-05

Start date

2017-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction. Ischaemic heart diseases

Interventions

Intervention 1: Intervention group: Two separated doses of 40 microgram adenosine in 10 ml normal saline 0.9% intracoronary infusion during primary PCI on LAD or LCX. Intervention 2: Control group: Tw

Prevention

Intervention group: Two separated doses of 40 microgram adenosine in 10 ml normal saline 0.9% intracoronary infusion during primary PCI on LAD or LCX.

Control group: Two separated doses of Intracoronary 10 ml normal saline 0.9% infusion in left coronary system.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: (a) ST elevation MI in ECG; (b) LAD and LCX lesion; (c) coronary lesion suitable for angioplasty; (d) TIMI flow 0-1. Exclusion criteria: (a) history of COPD or asthma; (b) patients who under treatment with dipyridamol; (c) Presentation with cardiogenic shock; (d) Patients who received fibrynolytic; (e) life expectancy less than 6 month; (f) stent thrombosis; (g) history of CABGs; (h) AV nodal block in first ECG; (I) TIMI flow 2-3 in angiography; (j) RCA lesion; (k) lack of patient satisfaction.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
ST elevation resolution. Timepoint: Before and after intervention. Method of measurement: ECG.;TIMI flow. Timepoint: Before and after intervention. Method of measurement: Angioplasty.;Level of CKMB and troponin. Timepoint: Before and after intervention. Method of measurement: Blood sample.	—

Secondary

Measure	Time frame
Inhospital mortality. Timepoint: After intervention. Method of measurement: check list.;Duration of hospitalization. Timepoint: After intervention. Method of measurement: check list.;Hemodynamic stability. Timepoint: After intervention. Method of measurement: check list.;Electrical stability. Timepoint: After intervention. Method of measurement: ECG.;Left ventricular ejection fraction. Timepoint: After intervention. Method of measurement: Echocardiography.	—

Measure

Time frame

Inhospital mortality. Timepoint: After intervention. Method of measurement: check list.;Duration of hospitalization. Timepoint: After intervention. Method of measurement: check list.;Hemodynamic stability. Timepoint: After intervention. Method of measurement: check list.;Electrical stability. Timepoint: After intervention. Method of measurement: ECG.;Left ventricular ejection fraction. Timepoint: After intervention. Method of measurement: Echocardiography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactManijeh Sajedi

Clinical Research Development Unit of Farshchian Heart Center, Department of Cardiology

manijehsajedi@yahoo.com+98 81 3838 1731

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026